STEPHEN HAHN to Adenocarcinoma
This is a "connection" page, showing publications STEPHEN HAHN has written about Adenocarcinoma.
Connection Strength
0.327
-
Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer. Lasers Surg Med. 2006 Jun; 38(5):427-34.
Score: 0.076
-
Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol. 2006; 25(1-2):373-87.
Score: 0.074
-
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma. Radiother Oncol. 2019 03; 132:55-62.
Score: 0.045
-
7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. Cancer. 2017 Aug 15; 123(16):3031-3039.
Score: 0.040
-
Long-Term Outcomes of Salvage Stereotactic Ablative?Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. J Thorac Oncol. 2017 06; 12(6):983-992.
Score: 0.040
-
Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 02; 12(2):281-292.
Score: 0.039
-
Comparative treatment planning between proton and X-ray therapy in pancreatic cancer. Med Dosim. 2001; 26(3):255-9.
Score: 0.013